Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologymhn paltusotine (Palsonify) Prior Auth Coverage | …
    Ask Trek AI about this page
    CurrentmhnPolicy CP.PHAR.755

    Paltusotine (Palsonify) for acromegaly

    Customize your policy alerts

    Sign up for mhn Policy CP.PHAR.755 alerts

    Get alerted when Policy CP.PHAR.755 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization requirements for paltusotine (Palsonify) in adults with acromegaly for Centene-affiliated health plans (Commercial, HIM, Medicaid) and specifies approval durations and step therapy expectations.

    Policy Summary
    Payermhn
    PolicyPaltusotine (Palsonify) for acromegaly
    Policy CodePolicy CP.PHAR.755
    Change TypeNo material changes
    Effective DateDec 1, 2025
    Next Review Date
    Key ActionPrior authorization required with submission of documentation demonstrating diagnostic criteria, endocrinologist involvement, age ≥18, prior therapies, and dosing within limits.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥18minimum age for coverage
    60 mg/daymaximum daily dose
    20 mg, 30 mgproduct strengths
    6 moinitial approval (Commercial)
    12 mo

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    initial approval (Medicaid/HIM)

    Coverage Criteria for Paltusotine (Palsonify)

    inv-01: Initial Therapy — Acromegaly — Covered when ALL of the following are met:

    Covered when ALL of the following are met:

    Acromegaly initial criteria: 1) Diagnosis of acromegaly evidenced by one of the following: (a) pre-treatment IGF-I above the upper limit of normal for age and sex for the reporting laboratory OR (b) serum growth hormone (GH) ≥ 1 µg/L after a 2-hour oral glucose tolerance test; 2) Prescription is by or in consultation with an endocrinologist; 3) Patient is ≥ 18 years of age; 4) Inadequate response to surgical resection or pituitary irradiation, or patient is not a candidate for such treatment; 5) Failure of Sandostatin® LAR Depot unless contraindicated or clinically adverse effects are experienced (prior authorization for Sandostatin LAR may be required); 6) Dose does not exceed both of the following: (a) 60 mg per day; and (b) 2 tablets per day.see node text

    Prior authorization required; approval durations: Medicaid/HIM 12 months; Commercial 6 months or to renewal date.

    inv-02: Continuation Therapy — Acromegaly — For continued therapy, ALL of the following must be met:

    For continued therapy, ALL of the following must be met:

    Acromegaly continuation criteria: 1) Member meets one of the following: (a) currently receiving medication via the Centene benefit or has previously met initial approval criteria; OR (b) currently receiving medication and enrolled in a state/product with continuity-of-care regulations; 2) Member is responding positively to therapy (e.g., improved GH or IGF-I serum concentrations or tumor mass control); 3) If a dose increase is requested, the new dose does not exceed both: (a) 60 mg per day; and (b) 2 tablets per day.see node text

    Approval durations: Medicaid/HIM 12 months; Commercial 6 months or to renewal date.

    inv-03: Other Diagnoses / Indications — Other uses not specifically covered by criteria:

    Other uses not specifically covered by criteria:

    Other indications: 1) If the drug has undergone a label change within the last 6 months that is not yet reflected in this policy, follow the applicable formulary/no-coverage or non-formulary policy for the relevant line of business (references: CP.CPA.190, HIM.PA.33, CP.PMN.255, HIM.PA.103, CP.PMN.16 as applicable); OR 2) If the requested use is not listed under section III (Diagnoses/Indications not authorized) and criterion 1 does not apply, refer to the off-label use policy for the applicable line of business (CP.CPA.09 for commercial, HIM.PA.154 for HIM, CP.PMN.53 for Medicaid).see node text

    References to specific Centene policy numbers provided in policy text.

    Non-FDA approved indications that are not specifically addressed by this policy are not authorized for coverage unless the request includes sufficient documentation of efficacy and safety consistent with the applicable off-label use policy or the member’s evidence of coverage document.

    Requests for use of paltusotine for non-FDA approved indications that lack adequate supporting documentation per the applicable off-label use policies (CP.CPA.09 for Commercial, HIM.PA.154 for Health Insurance Marketplace, or CP.PMN.53 for Medicaid) are considered not authorized (not medically necessary) under this policy.

    Product Availability and Dosing / Coding

    Product availability / dosing informationmixed
    NDC/HCPCS not specifiedNo specific NDC or HCPCS codes listed in policy; product strengths: Tablets 20 mg and 30 mg
    Paltusotine dosing - initialInitial: 40 mg PO QD (may be temporarily reduced to 20 mg PO QD during initiation based on tolerability)
    Paltusotine dosing - maintenanceMaintenance: after 2–4 weeks of 40 mg PO QD, may titrate to 60 mg PO QD based on IGF‑1 levels
    Maximum daily dose60 mg per day; dosing guidance indicates maximum 2 tablets per day (per policy thresholds)
    Maximum daily dose
    Maximum daily dose60 mg per day
    Maximum tablets per day2 tablets per day
    Typical maintenance titrationAfter 2–4 weeks at 40 mg PO QD, may titrate to 60 mg PO QD based on IGF‑I levels

    Prior Authorization, Documentation, and Step Therapy Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Submit documentation demonstrating diagnostic criteria for acromegaly, evidence of endocrinologist involvement, age ≥ 18 years, prior treatments (including surgical resection or pituitary irradiation status), and other supporting clinical information.

    • Required documentation: office chart notes, laboratory results (e.g., IGF-I, GH with oral glucose tolerance test), imaging or operative reports, and consultation notes.
    • Approval durations: Medicaid/HIM — 12 months; Commercial — 6 months or to the member's renewal date, whichever is longer.
    Note

    State-specific Step Therapy Exception (Illinois HIM)

    For Illinois HIM (health insurance marketplace) requests, the Sandostatin LAR Depot (octreotide acetate) step therapy requirement does not apply beginning 1/1/2026 per Illinois HB 5395.

    • Effective date of exception: 2026-01-01
    • Scope: Illinois HIM requests only

    Background

    Paltusotine (Palsonify) is a somatostatin receptor agonist indicated for adults with acromegaly who have had an inadequate response to surgical resection or who are not surgical candidates. Clinical response is assessed by changes in growth hormone (GH) and insulin-like growth factor I (IGF‑I)

    Diagnostic Criteria and Definitions

    Diagnostic criteria for acromegaly
    IGF‑I criterionPre‑treatment IGF‑I level above the age‑ and sex‑adjusted upper limit of normal for the reporting laboratory
    GH after OGTT criterionSerum growth hormone (GH) ≥ 1 µg/L after a 2‑hour oral glucose tolerance test
    Clinical corroborationDiagnosis should be established in the context of endocrine assessment and response to therapy is monitored by GH/IGF‑I and tumor control measures
    Policy Summary
    Payermhn
    PolicyPaltusotine (Palsonify) for acromegaly
    Policy CodePolicy CP.PHAR.755
    Change TypeNo material changes
    Effective DateDec 1, 2025
    Next Review Date
    Key ActionPrior authorization required with submission of documentation demonstrating diagnostic criteria, endocrinologist involvement, age ≥18, prior therapies, and dosing within limits.
    SourceLink
    On This Page
    Coverage Criteria for Paltusotine (Palsonify)Product Availability and Dosing / CodingPrior Authorization, Documentation, and Step Therapy RequirementsBackgroundDiagnostic Criteria and Definitions
    Step Therapy

    Step Therapy Requirement — Octreotide LAR

    Step therapy: prior failure of Sandostatin LAR Depot (octreotide acetate) is required before approval of Palsonify (paltusotine) unless the member has a contraindication to Sandostatin LAR or experienced clinically significant adverse effects.

    • If Sandostatin LAR Depot is contraindicated or produced intolerable adverse effects, document the specific contraindication or adverse event.
    • Prior authorization for Sandostatin LAR Depot may be required; document prior use and response when available.
    Documentation Required

    Required Clinical Documentation

    Provider must submit documentation (such as office chart notes, lab results, imaging, operative reports, or other clinical information) supporting that the member meets all approval criteria.

    • Documentation should confirm diagnosis criteria (e.g., elevated pre-treatment IGF-I for age/gender or GH ≥ 1 µg/L post-OGTT), endocrinologist involvement, age ≥ 18, prior surgical or radiation treatment status, and prior medication history.
    • Ensure documentation of dosing and therapeutic response or adverse effects to prior therapies when applicable.
    Denial Risk

    Unsupported Indication or Missing Documentation

    Requests for non-FDA approved (off-label) indications that are not addressed by this policy will not be authorized unless sufficient documentation is provided per applicable off-label use policies.

    • Commercial off-label policy: CP.CPA.09
    • HIM off-label policy: HIM.PA.154
    • Medicaid off-label policy: CP.PMN.53
    • Provide clinical evidence of efficacy and safety or evidence of coverage documentation to support approval for an unsupported indication.